Royalty Pharma plc (RPRX) To Go Ex-Dividend on May 16th

Royalty Pharma plc (NASDAQ:RPRX) announced a quarterly dividend on Monday, April 21st, Wall Street Journal reports. Stockholders of record on Friday, May 16th will be paid a dividend of 0.22 per share by the biopharmaceutical company on Tuesday, June 10th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date is Friday, May 16th.

Royalty Pharma has increased its dividend by an average of 7.3% per year over the last three years and has raised its dividend annually for the last 5 consecutive years. Royalty Pharma has a dividend payout ratio of 17.1% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $4.86 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 18.1%.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $32.82 on Wednesday. Royalty Pharma has a 12-month low of $24.05 and a 12-month high of $34.20. The firm has a market capitalization of $18.92 billion, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. The business has a 50 day simple moving average of $32.37 and a 200 day simple moving average of $29.86. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The business had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. On average, equities research analysts anticipate that Royalty Pharma will post 4.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on RPRX shares. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Monday. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.